The six-year study published in the medical journal The Lancet reported on 780 people living in south London, 410 of whom were being treated for conditions including schizophrenia and bipolar disorder.
The report's lead author was Marta Di Forti from the Institute of Psychiatry, Psychology and Neuroscience at King's College London, who warned about the growing use of "skunk" -- a powerful type of cannabis.
"Compared with those who had never tried cannabis, users of high potency skunk-like cannabis had a threefold increase in risk of psychosis," she said.
Psychosis is a mental health problem and the symptoms include hallucinations and delusions.
In England, about one new case of psychosis is diagnosed for every 2,000 people every year.
"This paper suggests that we could prevent almost one quarter of cases of psychosis if no-one smoked high potency cannabis," said Robin Murray, professor of psychiatric research at King's College London and a senior researcher for the study.
"This could save young patients a lot of suffering and the NHS (National Health Service) a lot of money," he said.
Researchers said today that it was important for doctors to ask not just about drug use but about frequency of drug use to assess the risk.
"This gives more information about whether the user is at risk of mental health problems. Awareness needs to increase for this to happen," Di Forti said.
A Home Office spokesman said the findings confirmed the government's hardline approach, adding: "Drugs such as cannabis are illegal because scientific and medical evidence demonstrates they are harmful."
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app